Hemolytic disease in fetuses and newborns due to antibodies against the M-antigen.
Páez M, Jiménez M, Corredor A.
Biomedica. 2021 Dec 15;41(4):643-650. doi: 10.7705/biomedica.5930.
Neonatal Blood Banking Practices.
Crowe EP, Goel R, Al-Mozain N, Josephson CD.
Clin Perinatol. 2023 Dec;50(4):821-837. doi: 10.1016/j.clp.2023.07.008. Epub 2023 Sep 20.
Neonatal hyperbilirubinemia due to ABO incompatibility: does blood group matter?
Akgül S, Korkmaz A, Yiğit S, Yurdakök M.
Turk J Pediatr. 2013 Sep-Oct;55(5):506-9.
Mechanisms of hemolysis.
Zipursky A.
Mead Johnson Symp Perinat Dev Med. 1982;(19):17-24.
A Comparative Analysis of the Efficacy of Blood Exchange Therapy in Neonatal Hyperbilirubinemia Induced by ABO and Rh Incompatibility.
Wu K, Chen L, Huang H, Chen D.
Int J Gen Med. 2024 Dec 9;17:5921-5927. doi: 10.2147/IJGM.S497184. eCollection 2024.
CD144+ endothelial microparticles as a marker of endothelial injury in neonatal ABO blood group incompatibility.
Awad HA, Tantawy AA, El-Farrash RA, Ismail EA, Youssif NM.
Blood Transfus. 2014 Apr;12(2):250-9. doi: 10.2450/2013.0101-13. Epub 2013 Nov 15.
Prediction of the development of neonatal hyperbilirubinemia in ABO incompatibility.
Chen JY, Ling UP.
Zhonghua Yi Xue Za Zhi (Taipei). 1994 Jan;53(1):13-8.
ABO hemolytic disease of the newborn: a need for clarity and consistency in diagnosis.
Watchko JF.
J Perinatol. 2023 Feb;43(2):242-247. doi: 10.1038/s41372-022-01556-6. Epub 2022 Nov 8.
[Efficacy and safety of intravenous immunoglobulins in the management of neonatal hyperbilirubinemia due to ABO incompatibility: a meta-analysis].
Cortey A, Elzaabi M, Waegemans T, Roch B, Aujard Y.
Arch Pediatr. 2014 Sep;21(9):976-83. doi: 10.1016/j.arcped.2014.02.005. Epub 2014 Aug 11.
Spectrum and outcome analysis of marked neonatal hyperbilirubinemia with blood group incompatibility.
Weng YH, Chiu YW.
Chang Gung Med J. 2009 Jul-Aug;32(4):400-8.
